Weekly Issue — 2025-07-13

GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide — have moved fast from diabetes clinics into mainstream weight care. Most of what parents hear about side effects still centers on nausea and constipation. But as prescriptions multiply, researchers are mining adverse-event databases and pooling trial data to catch the less-discussed signals. The two studies driving this piece are not the final word; they're a moderate-strength nudge to ask better questions at your next appointment.

The first analysis, published in The Laryngoscope, combed through the FDA's Adverse Event Reporting System (FAERS) for ear, nose and throat complaints tied to the five major GLP-1 drugs, from one year after each approval through the end of 2023. Across 9,746 reported adverse events, the standouts were not subtle: medullary and papillary thyroid carcinoma signals showed up across virtually all of the drugs, echoing a known boxed-warning concern, and reflux (GERD) was significant for every agent assessed.

The genuinely new texture is in the head-and-neck signals. Semaglutide — the molecule in Ozempic and Wegovy — flagged statistically for anosmia (loss of smell), dry mouth, dysgeusia (altered taste) and Bell's palsy. Liraglutide flagged for dysphonia (voice changes), dysgeusia, tinnitus and Bell's palsy. Exenatide showed signals including dysgeusia and hearing disability. None of this proves the drug caused the symptom in any given person — FAERS is a reporting system, not a controlled trial, and people on these medications are also losing weight, changing diets and aging in real time. But a signal strong enough to clear the authors' thresholds is a signal worth naming.

The second study, a systematic review and meta-analysis in The American Journal of Gastroenterology, asked a very practical question: do GLP-1 drugs make colonoscopy prep harder? Pooling five studies and 10,833 patients (about half on GLP-1s, half not), the authors found the GLP-1 group had roughly twice the odds of inadequate bowel preparation (odds ratio 2.10; 95% CI 1.41–3.13). Their mean Boston Bowel Preparation Scale score was also 0.34 points lower than controls — a small absolute gap, but enough to push some preps from "good enough" into "please come back and do this again."

The mechanism is intuitive: GLP-1s slow gastric emptying and gut motility, which is a feature for blood sugar and appetite and a bug when you're trying to flush the colon clean overnight. The authors don't tell patients to stop their medication; they make the case that gastroenterologists need clearer pre-procedure guidance. If you're a parent who finally booked the screening colonoscopy you've been putting off, that's the conversation to have a week ahead of time — not the night before.

The honest answer, with the evidence at this strength, is: informed, not alarmed. FAERS analyses describe reporting patterns; they cannot tell you your personal risk, and they tend to over-represent dramatic or novel events. Meta-analyses of observational colonoscopy data are stronger but still observational. Neither study changes the underlying calculus that, for the right patient, GLP-1s deliver meaningful benefits for blood sugar, weight and increasingly cardiovascular outcomes.

What they do is round out the consent conversation. If you're newly on a GLP-1 and notice a persistent change in taste, smell, voice or hearing, that's worth flagging to your prescriber rather than chalking up to a bad cold or a bad week. If you have a colonoscopy scheduled, your gastroenterologist needs to know you're on one of these drugs — there may be an extended liquid diet or a modified prep plan that gets you through on the first try.

None of this is a reason to panic-cancel a prescription that's working for you. It is a reason to treat these drugs the way you'd treat any powerful medication that's still revealing itself: with a good prescriber, honest symptom-tracking, and a low threshold for asking, "Is this normal?" The research is catching up to the prescriptions. Your job is just to stay in the conversation.

If you are a 40-year-old man tracking your visceral fat, your ALT, and your morning energy, this matters for a specific reason: the same molecule that quiets hunger appears to be quieting several of the downstream fires that midlife metabolic drift tends to light. Whether that earns GLP-1s a place in your protocol is a conversation for you and a clinician — but the case for treating them as a multi-system metabolic therapy, rather than a vanity injection, is no longer fringe.

Start with the liver, because that is where the human data is strongest. In a propensity-matched analysis of 15,176 pairs of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes drawn from the TriNetX network, patients started on a GLP-1 receptor agonist had a 16% lower risk of major adverse liver outcomes — decompensated cirrhosis, hepatocellular carcinoma, or liver transplantation — than patients started on an SGLT2 inhibitor. The reduction was driven primarily by fewer decompensation events. Both drug classes are good for the liver. GLP-1s look, in this dataset, modestly better.

A caveat before we go further: this is observational data, not a head-to-head randomized trial. The hazard ratio (0.84, 95% CI 0.73–0.97) is real but narrow, and the comparison is between two already-effective drug classes — not between GLP-1 and nothing. What it does suggest is that for men with the now-staggeringly-common combination of fatty liver and insulin resistance, the choice of glucose-lowering agent is also a choice about long-term liver trajectory.

One of the more provocative 2025 findings did not come from a human trial. Researchers fed mice a high-fat diet for 24 weeks — long enough to induce a fair imitation of human metabolic syndrome — then treated them for four weeks with semaglutide. The animals showed restored astrocyte coverage of cerebral vessels, reduced leukocyte-endothelium interactions, and improved blood-brain barrier integrity compared with saline controls. In plain English: the drug appeared to repair the seal between the bloodstream and the brain that chronic metabolic inflammation had been corroding.

This is the kind of result that deserves both attention and restraint. It is a mouse study. The leap from rodent cerebral microcirculation to human cognition in midlife is enormous. But it offers a mechanistic candidate for something clinicians have been observing anecdotally — patients on GLP-1s reporting clearer thinking that does not seem fully explained by weight loss alone — and it lines up with a broader hypothesis that obesity-related cognitive decline is partly a vascular problem the brain inherits from the rest of the body.

Then there is addiction, which is where the early signal is most intriguing and the data most preliminary. Recreational users of GLP-1 drugs have reported, almost in passing, that their interest in a second glass of wine or a late-night cigarette quietly evaporated. That observation is now being formally tested. The Danish SEMALCO trial — a 26-week, randomized, double-blinded, placebo-controlled study in 108 patients with alcohol use disorder and comorbid obesity — is measuring whether once-weekly semaglutide reduces heavy drinking days, with a subgroup undergoing structural, functional, and neurochemical brain imaging at baseline and at week 26.

The trial is a protocol, not a result. We do not yet know how it will read out. What we can say is that there are currently only three FDA-approved pharmacotherapies for alcohol use disorder, and the treatment gap is wide. A fourth — particularly one already in tens of millions of medicine cabinets — would matter. A separate 2025 review of the broader literature on peptide therapeutics and intrinsically disordered proteins also reframed GLP-1 RAs as a class with reduced addiction-related risk profiles relative to bariatric surgery, which has been associated with increased substance use post-operatively.

Underneath all of this, mechanism research is starting to catch up to clinical observation. A 2025 ceRNA network analysis of adipose tissue from obese mice treated with a GLP-1 RA found that the drug activates the PI3K-Akt and AMPK signaling pathways, with downstream reductions in SREBP-1, ACC, and FAS — the master switches of fat synthesis. That is a tidier story than "appetite suppressant." It suggests GLP-1 RAs are not just dialing down calories in, but actively reshaping how fat tissue handles fuel. Whether that intracellular rewiring is what carries the liver, brain, and craving benefits along with it is the open question.

The honest summary for a busy 40-year-old: if you are already a candidate for a GLP-1 because of weight, type 2 diabetes, or MASLD, the emerging evidence makes the case for the drug class somewhat stronger than it was a year ago, and gives you and your clinician more to weigh than waist circumference alone. If you are not a candidate, none of this is a reason to become one. The drug is not a longevity supplement, and the studies above do not say it is. What they do say is that a molecule designed to mimic a gut hormone is reaching into systems no one originally drew on the whiteboard — and that the next chapter of metabolic medicine is going to be written in places we used to think were unrelated.

The shift has a clunky name — adipocentric — but the idea is elegant. A 2025 review in the Journal of Clinical Medicine argues that most type 2 diabetes isn't really a blood-sugar disease at all. It's a fat-tissue disease that shows up as blood sugar, the way a smoke alarm shows up as noise. The authors call the underlying problem 'adiposopathy-related diabetes,' and they describe it with three features that should sound uncomfortably familiar to anyone navigating perimenopause: visceral fat creeping into places it doesn't belong, inflammatory signals leaking out of fat cells, and insulin that stops doing its job — a pattern spelled out in detail by the review's authors.

Translation: the fat around your organs isn't inert padding. It's an endocrine organ, and when it's unhappy, it talks — loudly, chemically, to your heart, liver, and pancreas.

Here's the frustrating part. A woman can lose ten pounds and still be carrying the metabolically dangerous kind of fat. Another can hold steady on the scale while her visceral fat — the deep, organ-hugging kind — quietly expands during the hormonal shifts of the late thirties and forties. Body weight is a blunt instrument. The new framing says we should be watching where fat sits and what it's doing, not just how much of it there is.

That's why the Journal of Clinical Medicine review pushes clinicians to prioritize visceral fat reduction as the goal of treatment intensification, not glycemic numbers alone. Done early enough — in people with shorter disease duration — the authors suggest this approach can even push type 2 diabetes into remission, while also delivering cardiovascular and kidney benefits. That's a moderate claim built on a review of existing evidence, not a guarantee, but it's a meaningful reframe.

There are now seven FDA-approved anti-obesity medications, and a 2025 review in Endocrinology and Metabolism Clinics of North America walks through all of them: phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. The authors are blunt about something that gets buried in TikTok-era enthusiasm: obesity is a chronic disease, and these medications are designed to be prescribed for long-term use — not a six-month sprint before a wedding.

The newer GLP-1 and dual GLP-1/GIP agonists are the ones doing the heavy cultural lifting, and for reason: their phase 3 trial data on weight reduction outstrip anything in the previous generation. But each of the seven drugs has its own mechanism, its own side-effect profile, and its own contraindications — which is the polite way of saying this is not a one-size-fits-all conversation, and it absolutely belongs in a clinician's office, not a comment section.

If the adipocentric argument has a closing statement, this is it. A separate 2025 review in Endocrinology and Metabolism Clinics of North America lays out the case that increased adiposity drives a long list of cardiovascular outcomes — coronary artery disease, heart failure, arrhythmias — through both direct mechanical strain and indirect chemical mischief. The authors call obesity a global public-health crisis and frame weight management as cardiovascular prevention, full stop.

The emerging GLP-1 signal is a big part of why. The same review notes that these drugs are producing remarkable weight reduction alongside cardiovascular prevention — a combination older weight-loss drugs never delivered. The authors are careful, though. They flag controversies and unresolved questions, and the evidence is best read as a strong, consistent signal rather than a settled verdict. Moderate confidence, not certainty.

For women in perimenopause, this matters in a specific way. Cardiovascular risk quietly accelerates after the menopausal transition, and visceral fat tends to expand even when the scale stays polite. A framework that treats fat tissue as a cardiovascular risk factor — instead of a cosmetic one — is, frankly, overdue.

You don't need a prescription pad to use the adipocentric lens. The same review that argues for it in pharmacology also leads with lifestyle modifications — the unsexy foundation that every drug protocol still sits on top of. Strength training, protein-forward eating, sleep, and stress management aren't substitutes for medical care when medical care is warranted, but they're the levers most directly under your control, and they happen to target the same visceral-fat, insulin-resistance, inflammation triangle the drugs are aimed at.

The deeper shift the science is asking for is mental. Stop asking the scale if you're winning. Start asking better questions: Is my waist measurement creeping up while my weight holds steady? Is my blood pressure drifting? Are my fasting labs telling a story my mirror isn't? Those are the signals the new framework wants you tracking. The number you've been staring at for twenty years was, it turns out, the least interesting one in the room.